Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 236

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 236
---
 Director of Aptorum Group, holds the remaining 10% shareholding of Aptorum Medical Limited.

Note 2: Angen Funds Limited, a company designated by an investor of ALS series projects, holds the remaining 20% shareholding of Acticule
Life Sciences Limited.

Note 3: An investor of project VLS-2 holds the remaining 10% shareholding of mTor (Hong Kong) Limited.

Currently, we conduct the
majority of our operations through the following subsidiaries: Aptorum Therapeutics Limited and Acticule Life Sciences Limited. All investments
into our company are into the parent company, Aptorum Group Limited, a Cayman Islands exempted company with limited liability whose principal
place of business is in Hong Kong; you may never hold direct equity interests in our subsidiaries or the VIEs.

In accordance with the provisions of Accounting
Standards Codification (“ASC”) 810, Consolidation, we consolidate any VIE of which we are regarded as the primary beneficiary
for accounting purposes. The typical condition for a controlling financial interest ownership is holding a majority of the voting interests
of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements that do not involve
controlling voting interests. We have determined that we have one VIE, namely, Libra, according to the U.S. GAAP. In accordance with ASC
810, we have considered Libra’s memorandum and article of association, and determined that we do not have such power over Libra’s
research and development activities, which activities most significantly impact Libra’s economic performance. Accordingly, we determined
that we are not regarded as the primary beneficiary of Libra for accounting purposes. Libra did not have any operations during the year
ended December 31, 2024.

<div align='center'>121

DiamiR</div>

Unless otherwise stated, all references to “DiamiR,” and similar designations in this section refer to DiamiR Biosciences Corp, a Delaware corporation, and its wholly-owned subsidiary DiamiR, LLC a private Delaware limited liability company.

Overview

DiamiR Biosciences Corp. (“DiamiR”) is a molecular diagnostic
company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s,
Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology developed at DiamiR is based on quantitative
analysis of circulating organ